- Home
- LNG vs TAK Comparison
LNG vs TAK Comparison
Compare LNG & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNG | TAK |
|---|---|---|
| Founded | 1983 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4B | 43.3B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | LNG | TAK |
|---|---|---|
| Price | $194.91 | $15.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $265.83 | N/A |
| AVG Volume (30 Days) | 2.1M | ★ 2.4M |
| Earning Date | 02-19-2026 | 01-29-2026 |
| Dividend Yield | 1.12% | ★ 3.36% |
| EPS Growth | ★ 14.15 | N/A |
| EPS | ★ 17.92 | 0.14 |
| Revenue | $18,937,000,000.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $30.79 | N/A |
| Revenue Next Year | $13.52 | $0.47 |
| P/E Ratio | ★ $11.09 | $112.61 |
| Revenue Growth | ★ 21.55 | N/A |
| 52 Week Low | $186.20 | $12.80 |
| 52 Week High | $257.65 | $15.78 |
Technical Indicators
Market Signals| Indicator | LNG | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 75.92 |
| Support Level | $191.64 | $15.48 |
| Resistance Level | $200.81 | $15.78 |
| Average True Range (ATR) | 3.81 | 0.18 |
| MACD | 1.54 | 0.05 |
| Stochastic Oscillator | 61.22 | 88.64 |
Price Performance
Historical ComparisonAbout LNG Cheniere Energy Inc.
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.